5T29
 
 | | Crystal structure of 10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2 | | Descriptor: | 10E8 EPITOPE SCAFFOLD T117V2, Antibody 10E8 FAB HEAVY CHAIN, Antibody 10E8 FAB LIGHT CHAIN, ... | | Authors: | Irimia, A, Wilson, I.A. | | Deposit date: | 2016-08-23 | | Release date: | 2017-03-08 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.03 Å) | | Cite: | Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.
PLoS Pathog., 13, 2017
|
|
5T3S
 | | HIV gp140 trimer MD39-10MUTA in complex with Fabs PGT124 and 35022 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein gp160, ... | | Authors: | Stanfield, R.L, Wilson, I.A. | | Deposit date: | 2016-08-26 | | Release date: | 2016-09-28 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (4.5 Å) | | Cite: | HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.
Immunity, 45, 2016
|
|
5TH0
 | |
5THC
 | |
5TGO
 | |
5T6L
 | | Crystal structure of 10E8 Fab in complex with the MPER epitope scaffold T117v2 | | Descriptor: | 10E8 EPITOPE SCAFFOLD T117V2, 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID, Antibody 10E8 FAB HEAVY CHAIN, ... | | Authors: | Irimia, A, Wilson, I.A. | | Deposit date: | 2016-09-01 | | Release date: | 2017-03-08 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.
PLoS Pathog., 13, 2017
|
|
5TFW
 | | Crystal structure of 10E8 Fab light chain mutant2 against the MPER region of the HIV-1 Env, in complex with T117v2 epitope scaffold | | Descriptor: | 1,2-ETHANEDIOL, 10E8 EPITOPE SCAFFOLD T117V2, Antibody 10E8 FAB HEAVY CHAIN, ... | | Authors: | Irimia, A, Wilson, I.A. | | Deposit date: | 2016-09-26 | | Release date: | 2017-03-08 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.168 Å) | | Cite: | Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.
PLoS Pathog., 13, 2017
|
|
5T6N
 | |
5T80
 | |
5TGU
 | |
5T85
 | |
5T6S
 | |
5C7K
 | | Crystal structure BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Antibody Fab 8ANC195 heavy chain, ... | | Authors: | Kong, L, Stanfield, R.L, Wilson, I.A. | | Deposit date: | 2015-06-24 | | Release date: | 2015-10-07 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (4.6019 Å) | | Cite: | Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer.
Acta Crystallogr.,Sect.D, 71, 2015
|
|
5TH1
 | |
5THF
 | |
5THB
 | |
5BZD
 | |
5BZW
 | |
5TGV
 | |
5CCK
 | |
5U7G
 | | Crystal Structure of the Catalytic Core of CBP | | Descriptor: | CREB-binding protein, ZINC ION | | Authors: | Park, S, Stanfield, R.L, Martinez-Yamout, M.M, Dyson, H.J, Wilson, I.A, Wright, P.E. | | Deposit date: | 2016-12-12 | | Release date: | 2017-06-21 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.401 Å) | | Cite: | Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation.
Proc. Natl. Acad. Sci. U.S.A., 114, 2017
|
|
5UEI
 | | Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 (Apo) | | Descriptor: | CHLORIDE ION, GLYCEROL, O13 | | Authors: | Gunn, R.J, Collins, B.C, McKitrick, T.R, Cummings, R.D, Herrin, B.R, Cooper, M.D, Wilson, I.A. | | Deposit date: | 2017-01-02 | | Release date: | 2017-10-18 | | Last modified: | 2019-12-11 | | Method: | X-RAY DIFFRACTION (1.702 Å) | | Cite: | Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.
Structure, 25, 2017
|
|
5UF4
 | | Crystal Structure of Variable Lymphocyte Receptor (VLR) O13 with LNnT bound | | Descriptor: | O13, beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-beta-D-galactopyranose-(1-4)-alpha-D-glucopyranose | | Authors: | Gunn, R.J, Collins, B.C, McKitrick, T.R, Cummings, R.D, Cooper, M.D, Herrin, B.R, Wilson, I.A. | | Deposit date: | 2017-01-03 | | Release date: | 2017-10-18 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.04 Å) | | Cite: | Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.
Structure, 25, 2017
|
|
5TZL
 | | Structure of transthyretin in complex with the kinetic stabilizer 201 | | Descriptor: | 4-(7-chloro-1,3-benzoxazol-2-yl)-2,6-diiodophenol, Transthyretin | | Authors: | Connelly, S, Mortenson, D.E, Choi, S, Wilson, I.A, Powers, E.T, Kelly, J.W, Johnson, S.M. | | Deposit date: | 2016-11-21 | | Release date: | 2017-06-28 | | Last modified: | 2023-11-15 | | Method: | X-RAY DIFFRACTION (1.4 Å) | | Cite: | Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Bioorg. Med. Chem. Lett., 27, 2017
|
|
5U65
 | | Camel Nanobody VHH-5 | | Descriptor: | SULFATE ION, VHH-5 | | Authors: | Stanfield, R.L, Wilson, I.A. | | Deposit date: | 2016-12-07 | | Release date: | 2017-09-20 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers.
Sci Rep, 7, 2017
|
|
